PURPOSE: To investigate the efficacy of sub-Tenon's capsule triamcinolone acetonide (STTA) injections for preventing development of intraocular inflammation (IOI) related to intravitreal injection (IVI) of brolucizumab for neovascular age-related macular degeneration (nAMD). METHODS: Consecutive patients with nAMD treated with brolucizumab IVIs were studied retrospectively. All eyes treated with brolucizumab in the clinic were switched from another anti-vascular endothelial growth factor agent. After the fourth case of IOI related to brolucizumab IVI, all eyes treated with brolucizumab received a STTA injection. The patients were divided into two groups: brolucizumab alone and brolucizumab combined with a STTA injection. RESULTS: Forty-four eyes (44 patients) treated with at least one brolucizumab IVI were studied: 14 eyes received brolucizumab IVI alone and 30 eyes received the combination therapy. IOI related to brolucizumab IVIs developed in four (28.6%) of 14 eyes in the brolucizumab group; IOI was severe in one eye, moderate in two eyes, and mild in one eye according to the HAWK and HARRIER trial definition; IOI did not develop in the 30 eyes that received combination therapy, the difference of which reached significance (p = 0.012). Regarding combination therapy, the intraocular pressure in three (10%) eyes increased to 22 to about 26 mmHg after the STTA injection and returned to normal range within 2 months without medication; no cataracts developed during this short mean follow-up period follow-up period of 7.1 ± 0.4 months. CONCLUSION: The results indicated the possible preventative effect of a STTA injection on development of brolucizumab-associated IOI.
PURPOSE: To investigate the efficacy of sub-Tenon's capsule triamcinolone acetonide (STTA) injections for preventing development of intraocular inflammation (IOI) related to intravitreal injection (IVI) of brolucizumab for neovascular age-related macular degeneration (nAMD). METHODS: Consecutive patients with nAMD treated with brolucizumab IVIs were studied retrospectively. All eyes treated with brolucizumab in the clinic were switched from another anti-vascular endothelial growth factor agent. After the fourth case of IOI related to brolucizumab IVI, all eyes treated with brolucizumab received a STTA injection. The patients were divided into two groups: brolucizumab alone and brolucizumab combined with a STTA injection. RESULTS: Forty-four eyes (44 patients) treated with at least one brolucizumab IVI were studied: 14 eyes received brolucizumab IVI alone and 30 eyes received the combination therapy. IOI related to brolucizumab IVIs developed in four (28.6%) of 14 eyes in the brolucizumab group; IOI was severe in one eye, moderate in two eyes, and mild in one eye according to the HAWK and HARRIER trial definition; IOI did not develop in the 30 eyes that received combination therapy, the difference of which reached significance (p = 0.012). Regarding combination therapy, the intraocular pressure in three (10%) eyes increased to 22 to about 26 mmHg after the STTA injection and returned to normal range within 2 months without medication; no cataracts developed during this short mean follow-up period follow-up period of 7.1 ± 0.4 months. CONCLUSION: The results indicated the possible preventative effect of a STTA injection on development of brolucizumab-associated IOI.
Authors: Frank G Holz; Pravin U Dugel; Georges Weissgerber; Robin Hamilton; Rufino Silva; Francesco Bandello; Michael Larsen; Andreas Weichselberger; Andreas Wenzel; Anne Schmidt; Dominik Escher; Laura Sararols; Eric Souied Journal: Ophthalmology Date: 2016-02-20 Impact factor: 12.079
Authors: Caroline R Baumal; Richard F Spaide; Lejla Vajzovic; K Bailey Freund; Scott D Walter; Vishak John; Ryan Rich; Nauman Chaudhry; Rohit R Lakhanpal; Patrick R Oellers; Thellea K Leveque; Bryan K Rutledge; Mark Chittum; Tommaso Bacci; Ana Bety Enriquez; Newman J Sund; Eric N P Subong; Thomas A Albini Journal: Ophthalmology Date: 2020-04-25 Impact factor: 12.079
Authors: Jonathan L Prenner; Lawrence S Halperin; Catherine Rycroft; Susan Hogue; Zinaria Williams Liu; Robert Seibert Journal: Am J Ophthalmol Date: 2015-07-02 Impact factor: 5.258
Authors: Pravin U Dugel; Glenn J Jaffe; Peter Sallstig; James Warburton; Andreas Weichselberger; Mark Wieland; Lawrence Singerman Journal: Ophthalmology Date: 2017-05-24 Impact factor: 12.079
Authors: Pravin U Dugel; Adrian Koh; Yuichiro Ogura; Glenn J Jaffe; Ursula Schmidt-Erfurth; David M Brown; Andre V Gomes; James Warburton; Andreas Weichselberger; Frank G Holz Journal: Ophthalmology Date: 2019-04-12 Impact factor: 12.079
Authors: Andre J Witkin; Paul Hahn; Timothy G Murray; J Fernando Arevalo; Kevin J Blinder; Netan Choudhry; Geoff G Emerson; Roger A Goldberg; Stephen J Kim; Joel Pearlman; Eric W Schneider; Homayoun Tabandeh; Robert W Wong Journal: J Vitreoretin Dis Date: 2020-07-01
Authors: Jordi Monés; Sunil K Srivastava; Glenn J Jaffe; Ramin Tadayoni; Thomas A Albini; Peter K Kaiser; Frank G Holz; Jean-Francois Korobelnik; Ivana K Kim; Christian Pruente; Timothy G Murray; Jeffrey S Heier Journal: Ophthalmology Date: 2020-11-15 Impact factor: 12.079
Authors: Michael Singer; Thomas A Albini; András Seres; Caroline R Baumal; Soumil Parikh; Richard Gale; Peter K Kaiser; Iryna Lobach; Nicolas Feltgen; Mayur R Joshi; Focke Ziemssen; Bahram Bodaghi Journal: Ophthalmol Retina Date: 2021-05-08